Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- PSTV
- Price
- 0.28
- Stock movement up
- +- (0.00%)
- Company name
- Plus Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 49.94M
- Ent value
- 50.27M
- Price/Sales
- 9.50
- Price/Book
- 9.88
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -26.52%
- 1 year return (CAGR)
- -76.67%
- 3 year return (CAGR)
- -10.46%
- 5 year return (CAGR)
- -38.29%
- 10 year return (CAGR)
- -56.09%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PSTV does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 9.50 |
| Price to Book | 9.88 |
| EV to Sales | 9.56 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 178.37M |
| EPS (TTM) | -0.02 |
| FCF per share (TTM) | -0.01 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.26M |
| Gross profit (TTM) | 4.67M |
| Operating income (TTM) | -13.46M |
| Net income (TTM) | -20.58M |
| EPS (TTM) | -0.02 |
| EPS (1y forward) | -0.15 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 88.87% |
| Operating margin (TTM) | -255.91% |
| Profit margin (TTM) | -391.33% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 13.29M |
| Net receivables | 0.00 |
| Total current assets | 17.59M |
| Goodwill | 372.00K |
| Intangible assets | 374.00K |
| Property, plant and equipment | 293.00K |
| Total assets | 18.67M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 21.00K |
| Total current liabilities | 13.62M |
| Total liabilities | 13.62M |
| Shareholder's equity | 5.05M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -15.73M |
| Capital expenditures (TTM) | 48.00K |
| Free cash flow (TTM) | -15.78M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -407.12% |
| Return on Assets | -110.21% |
| Return on Invested Capital | -405.44% |
| Cash Return on Invested Capital | -310.88% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.28 |
| Daily high | 0.29 |
| Daily low | 0.27 |
| Daily Volume | 4.19M |
| All-time high | 72000.00 |
| 1y analyst estimate | 5.50 |
| Beta | 0.85 |
| EPS (TTM) | -0.02 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| PSTV | S&P500 | |
| Current price drop from All-time high | -100.00% | -1.82% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 9 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -76.40% | -10.84% |
| Avg time to new high | 179 days | 12 days |
| Max time to new high | 5091 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
49.94M
Marketcap category
Small-cap
Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Employees
21
Website
Investor relations
-
SEC filings
CEO
Marc H. Hedrick
Country
USA
City
Austin
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page